The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Healthcare Investors Brace for Busy Week as U.S. Conference Kicks Off

Healthcare Investors Brace for Busy Week as U.S. Conference Kicks Off

January 11, 2016 • By Lewis Krauskopf

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Healthcare investors can expect a volatile week starting on Monday when the sector’s biggest financial event hits San Francisco.

You Might Also Like
  • U.S. Republicans Expected to Unveil Healthcare Bill This Week
  • Senate May Vote on Revised Healthcare Bill Next Week
  • Build Better Leaders: The 2018 ACR/ARHP Leadership Conference Focused on Practical Tips for Guiding Committees, Meetings & Conference Calls

The annual JP Morgan healthcare conference, in which many healthcare companies present product and financial news to would-be investors, has been credited for helping the January out-performance of the healthcare sector in recent years.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

But after a strong five-year period saw the sector grow to 15.2% of the S&P 500 index from 10.9% in 2010, investors are concerned that political threats to drug pricing and uncertainty about Obamacare could hurt the sector.

“There are probably 15 to 20 high profile companies that will give some formal guidance” at the conference, says David Heupel, a healthcare analyst at Thrivent Investment Management in Minneapolis. “You see either the group is in pretty good shape or maybe 2016 is going to be a little less robust than expectations.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The S&P healthcare sector is still reasonably priced relative to the broader market, with the index’s price roughly 16.1 times earnings expected over the next 12 months, compared to the 16.5 level for the S&P 500 index. And even at 15.2% of the S&P, healthcare stocks still make up less than the 17.4% that healthcare spending contributed to U.S. gross domestic product in 2013, the most recently aggregated data from the Bureau of Economic Analysis.

Listening for answers at the conference will be roughly 3,000 investors like Les Funtleyder, healthcare portfolio manager for E Squared Asset Management in New York.

“For the first part of the year, (the conference is) actually very important,” says Funtleyder. “It sets the tone.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

JP Morgan says it expects roughly 9,000 attendees and presentations from more than 400 biotech, pharmaceutical, medical device, health insurance and other healthcare companies, a similar amount to last year.

As individual companies take the podium at the conference, their shares could gyrate significantly.

For example, Celgene Corp, whose stock soared 17% during the week of the conference in 2013 after it issued a long-term outlook, is among companies expected to give key financial data this year, along with rival large-cap biotech firms Regeneron Pharmaceuticals and Vertex Pharmaceuticals.

The climate for deals, including those already struck and the outlook for more consolidation, will also be in focus.

Top executives at insurers Anthem and Aetna, both of which are trying to gain clearance for massive acquisitions, could give investors more confidence those deals will pass anti-trust scrutiny.

Shire Pharmaceuticals Plc could also announce a roughly $32.5 billion acquisition of fellow rare disease drugmaker Baxalta International Inc. as early as Monday, sources have told Reuters. The conference could also shed light on whether the sector can sustain its feverish deal-making pace.

Pages: 1 2 | Single Page

Filed Under: Pharma Co. News, Professional Topics Tagged With: Affordable Care Act, Health Insurance, Obamacare, pharmaceutical company

You Might Also Like:
  • U.S. Republicans Expected to Unveil Healthcare Bill This Week
  • Senate May Vote on Revised Healthcare Bill Next Week
  • Build Better Leaders: The 2018 ACR/ARHP Leadership Conference Focused on Practical Tips for Guiding Committees, Meetings & Conference Calls
  • Republicans Pull Healthcare Legislation

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.